PATRICK W. PACE, M.D. - Corporate Board Profile

ENCISION INC

Filing Date	Source Excerpt
2014-07-11	Patrick W. Pace, M.D. (2) 42 Director (2)Member of the Nominating Committee ... The following table details the total compensation earned by our non-employee directors in fiscal year 2014. ... Patrick W. Pace, M.D. 20,000.00 29,691.00 89,519.00 (3) 139,210.00 ... The nominating committee members are Robert H. Fries, Vern D. Kornelsen and Patrick W. Pace, M.D.
2015-07-30	Patrick W. Pace, M.D. was appointed to our board of directors in April 2012. Dr. Pace is the owner of PICO LLC, a healthcare consulting firm. He also serves as Executive Chairman of Nanospectra Biosciences, a medical device company that focuses on the use of nanoparticles in the treatment of a variety of diseases, as an Advisor to EDG Partners, a healthcare private equity investment firm, and as a board member of MMIS, a global technology company that provides compliance and business intelligence solutions for the life science industry. Dr. Pace began his career as a resident in Otolaryngology (ENT) at the University of Virginia Hospital. After leaving a career in medicine for the investment world, he spent several years in equities at Credit Suisse and UBS, culminating in a role as a Senior Research Analyst covering medical devices. He then led healthcare high yield and distressed debt investing as part of AIG Investments. After AIG, he served as Managing Director at Citadel Investment Group and helped launch its effort in investment banking. Dr. Pace received a Bachelor of Arts, with Honors in Psychology, from Vanderbilt University and a Doctor of Medicine from The University of Texas Medical School at Houston. We believe that Dr. Pace’s healthcare and investment experience give him the qualifications and skills to serve as a director. He is a member of the Nominating Committee. He received total compensation of $39,000 in fiscal year 2015.
2016-07-08	Patrick W. Pace, M.D. was appointed to our board of directors in April 2012. Dr. Pace is a Director on UTIMCO’s investment team and maintains responsibility for leading investment strategies in the private equity lower middle market arena and in healthcare across the endowments. He joined UTIMCO after working with EDG Partners as an Advisor. Previously, Dr. Pace served as Managing Director at Citadel Investment Group. Prior to Citadel, he led healthcare high yield and distressed debt investing as part of AIG Investments, served as a Senior Analyst covering the medical device industry at UBS, and worked in Equities at Credit Suisse First Boston. Dr. Pace began his career as a resident in Otolaryngology (ENT) at the University of Virginia Hospital. Dr. Pace serves on the board of MMIS, Inc, and Executive Chairman of Nanospectra Biosciences. He serves on the Advisory Council for the UT-Health School of Biomedical Informatics and on the Investment Committee for the Seton Fund. Dr. Pace received a Bachelor of Arts, with Honors in Psychology, from Vanderbilt University and a Doctor of Medicine from The University of Texas Medical School at Houston. We believe that Dr. Pace’s healthcare and investment experience give him the qualifications and skills to serve as a director. (2)Member of the Nominating Committee. Our independent directors currently receive $1,250 a quarter for their services and are reimbursed for their out-of-pocket expenses incurred in connection with their service as directors. Option or equity grants to our directors are at the discretion of the board of directors. The following table details the total compensation earned by our non-employee directors in fiscal year 2016. Patrick W. Pace, M.D.: Fees paid in cash $6,250, Equity compensation $5,000, All other compensation $0, Total $11,250.
2017-07-11	Patrick W. Pace, M.D. 46 Director (2)Member of the Nominating Committee. (3)Member of the Audit Committee. Our independent directors currently receive $1,250 a quarter for their services and are reimbursed for their out-of-pocket expenses incurred in connection with their service as directors. Option or equity grants to our directors are at the discretion of the board of directors. Director Compensation table shows Patrick W. Pace, M.D. total compensation as $7,003.
2018-06-11	Patrick W. Pace, M.D. 46 Director (2)Member of the Nominating Committee. (3)Member of the Audit Committee. Our independent directors currently receive $1,250 a quarter for their services... The following table details the total compensation earned by our non-employee directors in fiscal year 2018. Patrick W. Pace, M.D. Fees paid in cash $5,000 Equity compensation $4,987 Total $9,987.
2019-06-21	Patrick W. Pace, M.D. was appointed to our board of directors in April 2012. Dr. Pace is a Senior Director on UTIMCO’s investment team and maintains responsibility for leading investment strategies in the private equity lower middle market arena and in healthcare across the endowments. He joined UTIMCO after working with EDG Partners as an Advisor. Previously, Dr. Pace served as Managing Director at Citadel Investment Group. Prior to Citadel, he led healthcare high yield and distressed debt investing as part of AIG Investments, served as a Senior Analyst covering the medical device industry at UBS, and worked in Equities at Credit Suisse First Boston. Dr. Pace began his career as a resident in Otolaryngology (ENT) at the University of Virginia Hospital. Dr. Pace serves on the board of MMIS, Inc., and Executive Chairman of Nanospectra Biosciences. He serves on the Advisory Council for the UT-Health School of Biomedical Informatics and on the Investment Committee for the Seton Fund. Dr. Pace received a Bachelor of Arts, with Honors in Psychology, from Vanderbilt University and a Doctor of Medicine from The University of Texas Medical School at Houston. We believe that Dr. Pace’s healthcare and investment experience give him the qualifications and skills to serve as a director. Our independent directors currently receive $1,250 a quarter for their services and are reimbursed for their out-of-pocket expenses incurred in connection with their service as directors. Option or equity grants to our directors are at the discretion of the board of directors. The following table details the total compensation earned by our non-employee directors in fiscal year 2019. Patrick W. Pace, M.D.: Fees paid in cash $5,000, Stock awards $0, Option awards $9,343, All other compensation $0, Total $14,343. He is a member of the Nominating Committee and Audit Committee.
2020-06-30	Patrick W. Pace, M.D. was appointed to our board of directors in April 2012. Dr. Pace is a Managing Director on UTIMCO’s Private Equity team and oversees all investments in private equity, venture capital, and private credit globally. Also, he is on UTIMCO’s Leadership Team and Investment Committee. Dr. Pace joined UTIMCO after working with EDG Partners as an Advisor. Previously, he served as Managing Director at Citadel Investment Group. Prior to Citadel, Dr. Pace led healthcare high yield and distressed debt investing as part of AIG Investments, served as a Senior Analyst covering the medical device industry at UBS, and worked in equities at Credit Suisse First Boston. Dr. Pace began his career as a resident in Otolaryngology (ENT) at the University of Virginia Hospital. Dr. Pace serves on the boards of MMIS, Inc, and as Chairman of Nanospectra Biosciences. He participates on the Advisory Council for the UT-Health School of Biomedical Informatics and on the Investment Committee for the St. David’s Foundation. He received a Bachelor of Arts, with Honors in Psychology, from Vanderbilt University and a Doctor of Medicine from The University of Texas Medical School at Houston. We believe that Dr. Pace’s healthcare and investment experience give him the qualifications and skills to serve as a director. (2) Member of the Nominating Committee. (3) Member of the Audit Committee. Our independent directors receive $1,250 a quarter for their services and are reimbursed for their out-of-pocket expenses incurred in connection with their service as directors. Option or equity grants to our directors are at the discretion of the board of directors. The following table details the total compensation earned by our non-employee directors in fiscal year 2020. Director Compensation: Patrick W. Pace, M.D. Fees paid in cash $5,000, Equity compensation $3,627, Total $8,627.
2021-06-30	Patrick W. Pace, M.D. was appointed to our board of directors in April 2012. Dr. Pace is a Managing Director on UTIMCO’s Private Equity team and oversees all investments in private equity, venture capital, and private credit globally. Also, he is on UTIMCO’s Leadership Team and Investment Committee. Dr. Pace joined UTIMCO after working with EDG Partners as an Advisor. Previously, he served as Managing Director at Citadel Investment Group. Prior to Citadel, Dr. Pace led healthcare high yield and distressed debt investing as part of AIG Investments, served as a Senior Analyst covering the medical device industry at UBS, and worked in equities at Credit Suisse First Boston. Dr. Pace began his career as a resident in Otolaryngology (ENT) at the University of Virginia Hospital. Dr. Pace serves on the boards of MMIS, Inc, and as Chairman of Nanospectra Biosciences. He participates on the Advisory Council for the UT-Health School of Biomedical Informatics and on the Investment Committee for the St. David’s Foundation. He received a Bachelor of Arts, with Honors in Psychology, from Vanderbilt University and a Doctor of Medicine from The University of Texas Medical School at Houston. We believe that Dr. Pace’s healthcare and investment experience give him the qualifications and skills to serve as a director. Compensation: Our independent directors receive $1,250 a quarter for their services and are reimbursed for their out-of-pocket expenses incurred in connection with their service as directors. Option or equity grants to our directors are at the discretion of the board of directors. The following table details the total compensation earned by our non-employee directors in fiscal year 2021. Director Compensation: Patrick W. Pace, M.D. Fees paid in cash $5,000, Equity compensation $3,369, Total $8,369.
2022-07-08	The following table sets forth the members of our board of directors, their ages as of March 31, 2022, and their positions and offices held: Patrick W. Pace, M.D. 50 Director. (2) Member of the Nominating Committee. (3) Member of the Audit Committee. Our independent directors receive $1,250 a quarter for their services and are reimbursed for their out-of-pocket expenses incurred in connection with their service as directors. Option or equity grants to our directors are at the discretion of the board of directors. The following table details the total compensation earned by our non-employee directors in fiscal year 2021. Director Compensation: Patrick W. Pace, M.D. Fees paid in cash $5,000, Equity compensation $3,989, Total $8,989.
2023-07-05	Patrick W. Pace, M.D. (2) (3) 51 Director (2) Member of the Nominating Committee. (3) Member of the Audit Committee. Our independent directors receive $1,250 a quarter for their services and are reimbursed for their out-of-pocket expenses incurred in connection with their service as directors. The following table details the total compensation earned by our non-employee directors in fiscal year 2023. Director Compensation Name Fees paid in cash ($) (1) Equity compensation ($) (2) All other compensation ($) Total ($) Patrick W. Pace, M.D. 5,000 5,660 ― 10,660 (1) The following table provides a breakdown of fees paid in cash. Name Annual retainers ($) Patrick W. Pace, M.D. 5,000
2024-06-27	The following table details the total compensation earned by our non-employee directors in fiscal year 2024. Director Compensation Name Fees paid in cash ($) (1) Equity compensation ($) (2) All other compensation ($) Total ($) Patrick W. Pace, M.D. 5,000 6,723 — 11,723